patients n | Median overall survival (months) | 95 % CI | p | |
---|---|---|---|---|
Total | 91 | 21 | 16–26 | |
Age (years) | ||||
≤65 | 41 | 27 | 21–33 | 0.1754 |
>65 | 50 | 19 | 16–22 | |
Gender | ||||
Female | 41 | 26 | 18–34 | 0.8796 |
Male | 50 | 20 | 15–25 | |
UICC stage | ||||
IIa | 29 | 27 | 13–40 | 0.3347 |
IIb | 62 | 20 | 16–24 | |
Grading | ||||
G1 and G2 | 55 | 26 | 1–31 | 0.0474 |
G3 | 36 | 15 | 8–22 | |
Perineural invasion | ||||
Pn0 | 32 | 19 | 9–29 | 0.7835 |
Pn1 | 59 | 21 | 16–26 | |
Vene invasion | ||||
V0 | 74 | 23 | 16–30 | 0.5583 |
V1 | 17 | 21 | 17–25 | |
Lymphatic invasion | ||||
L0 | 50 | 24 | 18–29 | 0.9821 |
L1 | 41 | 21 | 15–26 | |
Resection margin | ||||
R0 | 77 | 23 | 15–31 | 0.3653 |
R1 | 24 | 18 | 16–26 | |
Type of surgery | ||||
Pancreatic head resection | 75 | 32 | 17–25 | 0.2475 |
Traverso-Longmire | 66 | |||
Whipple-Kausch | 9 | |||
Pancreatic left resection | 16 | 21 | 14–49 | |
Adjuvant gemcitabine | ||||
Yes | 64 | 31 | 24–37 | 2.9922E-8 |
No | 27 | 12 | 9–14 |